CXCR4 and mantle cell lymphoma: More recently, a study reported the application of a CRISPR-Cas9 system to disrupt CXCR4 expression in mantle cell lymphomas (MCL), a highly aggressive subset of B-cell non-Hodgkin lymphomas (NHLs).